0000-0003-2955-9820 Employment
-
The University of Sydney Professor of Oncology
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (149)
- Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplifications: a molecular screening and therapeutics (MoST) program substudy Save
- Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program Save
- Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping Review Save
- Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell Carcinoma Save
- Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized Studies Save
- Response to Letter to the Editor entitled “Methodological considerations in assessing the clinical impact of TP53 classifications in advanced NSCLC” Save
- Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Save
- Genomic Therapy Matching in Rare and Refractory Cancers. Save
- Heterogeneity of treatment effect? What baseline prognostic factors tell us about immunotherapy benefit Save
- Time to achieve response and depth of maximal tumor response as potential surrogates for overall survival in advanced non-small cell lung cancer Save